1-6 of 6
Mahmoud Hashim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Investigation of Potential Treatment Effect Modifiers in Multiple Myeloma from Published Randomized Controlled Trials

Jianming He, Karen Chiang, Xiwu Lin, John Maringwa, Lingfeng Yang, Jackie Kwong, Sandhya Nair, Mahmoud Hashim, Imtiaz Samjoo
Journal: Blood
Blood (2024) 144 (Supplement 1): 7827.
https://doi.org/10.1182/blood-2024-200922
Published: 2024
Journal Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios

Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar
Journal: Blood
Blood (2021) 138 (Supplement 1): 118.
https://doi.org/10.1182/blood-2021-144914
Published: 2021
Journal Articles

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Pieter Sonneveld, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Thierry Facon, MD, Cyrille Hulin, MD, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, MD, Sarah Cote, Philippe Moreau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4739.
https://doi.org/10.1182/blood-2019-122775
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3553.
https://doi.org/10.1182/blood-2018-99-113157
Published: 2018